Literature DB >> 19588333

Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Richard P Mattick1, Courtney Breen, Jo Kimber, Marina Davoli.   

Abstract

BACKGROUND: Methadone maintenance was the first widely used opioid replacement therapy to treat heroin dependence, and it remains the best-researched treatment for this problem. Despite the widespread use of methadone in maintenance treatment for opioid dependence in many countries, it is a controversial treatment whose effectiveness has been disputed.
OBJECTIVES: To evaluate the effects of methadone maintenance treatment (MMT) compared with treatments that did not involve opioid replacement therapy (i.e., detoxification, offer of drug-free rehabilitation, placebo medication, wait-list controls) for opioid dependence. SEARCH STRATEGY: We searched the following databases up to Dec 2008: the Cochrane Controlled Trials Register, EMBASE, PubMED, CINAHL, Current Contents, Psychlit, CORK [www. state.vt.su/adap/cork], Alcohol and Drug Council of Australia (ADCA) [www.adca.org.au], Australian Drug Foundation (ADF-VIC) [www.adf.org.au], Centre for Education and Information on Drugs and Alcohol (CEIDA) [www.ceida.net.au], Australian Bibliographic Network (ABN), and Library of Congress databases, available NIDA monographs and the College on Problems of Drug Dependence Inc. proceedings, the reference lists of all identified studies and published reviews; authors of identified RCTs were asked about other published or unpublished relevant RCTs. SELECTION CRITERIA: All randomised controlled clinical trials of methadone maintenance therapy compared with either placebo maintenance or other non-pharmacological therapy for the treatment of opioid dependence. DATA COLLECTION AND ANALYSIS: Reviewers evaluated the papers separately and independently, rating methodological quality of sequence generation, concealment of allocation and bias. Data were extracted independently for meta-analysis and double-entered. MAIN
RESULTS: Eleven studies met the criteria for inclusion in this review, all were randomised clinical trials, two were double-blind. There were a total number of 1969 participants. The sequence generation was inadequate in one study, adequate in five studies and unclear in the remaining studies. The allocation of concealment was adequate in three studies and unclear in the remaining studies. Methadone appeared statistically significantly more effective than non-pharmacological approaches in retaining patients in treatment and in the suppression of heroin use as measured by self report and urine/hair analysis (6 RCTs, RR = 0.66 95% CI 0.56-0.78), but not statistically different in criminal activity (3 RCTs, RR=0.39; 95%CI: 0.12-1.25) or mortality (4 RCTs, RR=0.48; 95%CI: 0.10-2.39). AUTHORS'
CONCLUSIONS: Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy. It does not show a statistically significant superior effect on criminal activity or mortality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19588333      PMCID: PMC7097731          DOI: 10.1002/14651858.CD002209.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  20 in total

1.  A randomized controlled trial of interim methadone maintenance: 10-Month follow-up.

Authors:  Robert P Schwartz; Jerome H Jaffe; David A Highfield; Jason M Callaman; Kevin E O'Grady
Journal:  Drug Alcohol Depend       Date:  2006-06-21       Impact factor: 4.492

2.  Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study.

Authors:  Thomas Clausen; Katinka Anchersen; Helge Waal
Journal:  Drug Alcohol Depend       Date:  2007-12-21       Impact factor: 4.492

3.  Methadone treatment of randomly selected criminal addicts.

Authors:  V P Dole; J W Robinson; J Orraca; E Towns; P Searcy; E Caine
Journal:  N Engl J Med       Date:  1969-06-19       Impact factor: 91.245

4.  Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one-year follow-up.

Authors:  R N Bale; W W Van Stone; J M Kuldau; T M Engelsing; R M Elashoff; V P Zarcone
Journal:  Arch Gen Psychiatry       Date:  1980-02

5.  The Swedish methadone maintenance program: a controlled study.

Authors:  L M Gunne; L Grönbladh
Journal:  Drug Alcohol Depend       Date:  1981-06       Impact factor: 4.492

6.  Heroin addiction--a metabolic disease.

Authors:  V P Dole; M E Nyswander
Journal:  Arch Intern Med       Date:  1967-07

7.  A randomized controlled trial of interim methadone maintenance.

Authors:  Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes
Journal:  Arch Gen Psychiatry       Date:  2006-01

Review 8.  Substitution treatment of injecting opioid users for prevention of HIV infection.

Authors:  L Gowing; M Farrell; R Bornemann; R Ali
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

9.  A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

Authors:  V P DOLE; M NYSWANDER
Journal:  JAMA       Date:  1965-08-23       Impact factor: 56.272

10.  Exposure to opioid maintenance treatment reduces long-term mortality.

Authors:  Amy Gibson; Louisa Degenhardt; Richard P Mattick; Robert Ali; Jason White; Susannah O'Brien
Journal:  Addiction       Date:  2008-01-08       Impact factor: 6.526

View more
  474 in total

1.  Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

Authors:  Shannon Gwin Mitchell; Jan Gryczynski; Sharon M Kelly; Kevin E O'Grady; Jerome H Jaffe; Yngvild K Olsen; Robert P Schwartz
Journal:  J Drug Issues       Date:  2014-01

Review 2.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

3.  Spatial patterns of arrests, police assault and addiction treatment center locations in Tijuana, Mexico.

Authors:  Dan Werb; Steffanie A Strathdee; Alicia Vera; Jaime Arredondo; Leo Beletsky; Patricia Gonzalez-Zuniga; Tommi Gaines
Journal:  Addiction       Date:  2016-04-28       Impact factor: 6.526

4.  Pharmacotherapy for Substance Use Disorders in Youths.

Authors:  Christopher J Hammond; Kevin M Gray
Journal:  J Child Adolesc Subst Abuse       Date:  2016-04-20

5.  Increasing availability of benzodiazepines among people who inject drugs in a Canadian setting.

Authors:  Geoffrey Walton; Huiru Dong; M J Milloy; Kora DeBeck; Thomas Kerr; Evan Wood; Kanna Hayashi
Journal:  Subst Abus       Date:  2017-09-18       Impact factor: 3.716

Review 6.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

7.  Justice Involvement and Treatment Use Among Rural Veterans.

Authors:  Andrea K Finlay; Alex H S Harris; Joel Rosenthal; Jessica Blue-Howells; Sean Clark; Bessie Flatley; Christine Timko
Journal:  Rural Ment Health       Date:  2018-01

8.  "This is not who I want to be:" experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment.

Authors:  Sarah K Moore; Honoria Guarino; Lisa A Marsch
Journal:  Subst Use Misuse       Date:  2013-09-16       Impact factor: 2.164

9.  Brief video intervention to improve attitudes throughout medications for opioid use disorder in a correctional setting.

Authors:  Jeffrey A Lam; Hye In Sarah Lee; Ashley Q Truong; Alexandria Macmadu; Jennifer G Clarke; Josiah Rich; Brad Brockmann
Journal:  J Subst Abuse Treat       Date:  2019-06-10

10.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.